A novel strategy using injectable and thermosensitive hydrogels has been developed to achieve the targeted and prolonged delivery of Herceptin, an antibody used in the treatment of HER2+ breast tumors [201]. This evidence concerns the gene ERBB2 and breast neoplasm.